The FDA will closely review the drug company data on the safe results of the drug, molnupiravir, before making a decision.
“The value here is that it’s a pill so you don’t have to deal with the infusion centers and all the factors around that,” said Dr. Nicholas Kartsonis, a senior vice president with Merck’s infectious disease unit in the article. “I think it’s a very powerful tool to add to the toolbox.”
About 68 million eligible Americans are unvaccinated, and heath authorities are believing a potential surge could crop up again as more people remain indoors this fall and winter season.
Read the full story here.